

Special Issue

Evolving Chemotherapies in Glioblastomas(GBM)–Present and Future

Message from the Guest Editors

Glioblastomas (GBM) have remained challenging to treat despite the innovative and revolutionary research taking place worldwide. The current standard of care for GBM, which includes surgery, radiation and chemotherapy with the blood–brain barrier (BBB)-permeable drug temozolomide (TMZ), has not been shown to be capable of extending the median survival time of GBM patients beyond 14.5 months. The response to TMZ is further dampened in O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated patients. The results of various large-scale clinical trials using immune-checkpoint blockades have predicted depressing outcomes for GBM patients. An almost 100% recurrence rate, a highly immunosuppressive environment, heterogeneity and an intact BBB in the peritumoral region of the brain makes most of the therapies ineffective. Various emerging chemotherapy regimens are under development and/or in clinical trials which have shown promise in preclinical models by overcoming the uncondusive GBM environment. In this Special Issue, we want to discuss all such chemotherapy-based studies that give hope to patients and to the field of GBM and are the path forward for research into GBM.

Guest Editors

Dr. Crismita Dmello

Department of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA

Dr. Fatima Khan

Department of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA

Deadline for manuscript submissions

closed (28 July 2023)



Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/140635

Life

Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/

[life](https://mdpi.com/journal/life)





Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
life](https://mdpi.com/journal/life)



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)